Logo

LXEO

Lexeo Therapeutics, Inc. Common Stock

LXEO

Lexeo Therapeutics, Inc. Common Stock • NASDAQ
$9.86 ▲ 2.39% (+0.23)
Market Cap $719.65 M
52w High $10.38
52w Low $1.45
Dividend Yield 0%
P/E -3.94
Volume 781.44K
Outstanding Shares 72.99M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $21.118M ▼ $-20.283M ▲ 0% $-0.33 ▲ $-19.731M ▲
Q2-2025 $0 $30.178M ▼ $-26.103M ▲ 0% $-0.6 ▲ $-25.534M ▲
Q1-2025 $0 $33.805M ▲ $-32.656M ▼ 0% $-0.99 ▼ $-32.115M ▼
Q4-2024 $0 $27.382M ▼ $-25.924M ▲ 0% $-0.78 ▲ $-25.373M ▲
Q3-2024 $0 $31.543M $-29.489M 0% $-0.89 $-28.945M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $40.996M ▼ $143.844M ▼ $23.013M ▼ $120.831M ▼
Q2-2025 $132.893M ▲ $176.068M ▲ $37.85M ▲ $138.218M ▲
Q1-2025 $99.831M ▼ $125.69M ▼ $37.575M ▲ $88.115M ▼
Q4-2024 $121.518M ▼ $146.942M ▼ $30.1M ▼ $116.842M ▼
Q3-2024 $157.02M $173.865M $34.539M $139.326M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-20.283M ▲ $-29.547M ▼ $35.011M ▲ $52K ▼ $5.516M ▼ $-29.836M ▼
Q2-2025 $-26.103M ▲ $-27.219M ▼ $-39.174M ▼ $72.96M ▲ $6.567M ▲ $-27.327M ▼
Q1-2025 $-32.656M ▼ $-21.716M ▲ $15.6M ▲ $11K ▲ $-6.105M ▲ $-21.716M ▲
Q4-2024 $-25.924M ▲ $-28.326M ▼ $-93.583M ▼ $-97K ▼ $-122.006M ▼ $-28.313M ▼
Q3-2024 $-29.489M $-17.806M $-83K $-72K $-17.961M $-17.889M

Five-Year Company Overview

Income Statement

Income Statement Lexeo is still a pure R&D company with no product revenue yet. Its income statement is dominated by research and development and other operating costs, which have led to steady, meaningful losses each year. Per‑share losses have deepened over time as the company has scaled its pipeline and public-company infrastructure. This pattern is typical of a clinical‑stage biotech: value is being built through science and trials, not yet through sales or profits, and future results will be highly sensitive to clinical and regulatory outcomes.

Balance Sheet

Balance Sheet The balance sheet shows a young company that has recently strengthened its financial footing. Total assets and cash have grown compared with the earliest years, helped by outside capital and the IPO, and shareholders’ equity has moved from negative to positive territory. Debt is present but appears modest relative to equity and assets, suggesting limited balance-sheet leverage. That said, the asset base is still fairly small, and the company remains dependent on its cash reserves and access to future financing to support multi‑year development plans.

Cash Flow

Cash Flow Cash flows reflect a classic early‑stage biotech profile: consistent cash outflows from operations as the company funds trials, payroll, and overhead, with free cash flow also negative. There is little to no heavy spending on physical assets, so cash burn is mainly driven by research and corporate expenses rather than large capital projects. This means the company’s future depends on careful cash management and timely access to new funding as programs move into more expensive late‑stage studies.

Competitive Edge

Competitive Edge Lexeo is trying to build a defensible niche in gene therapy by focusing on genetically defined cardiovascular conditions and a subset of Alzheimer’s disease. Its use of a specialized AAVrh.10 gene delivery vector, combined with expertise in cardiac gene therapy, gives it a differentiated technical angle versus more generalized gene therapy players. Regulatory designations and exclusive academic licenses help strengthen its position. However, it still operates in an intensely competitive area with larger, better‑funded rivals, and its ultimate competitive standing will hinge on how its clinical data compare with alternative therapies over time.

Innovation and R&D

Innovation and R&D Innovation is the core of Lexeo’s story. The company is advancing multiple clinical programs that aim to correct underlying genetic drivers of disease, including gene therapies for a rare inherited cardiomyopathy, a specific arrhythmogenic heart disease, and APOE4‑associated Alzheimer’s. Its platform is built around a targeted viral vector with strong heart and nervous system delivery, and it is already expanding into next‑generation non‑viral and RNA‑based approaches. R&D spending is substantial relative to the company’s size, reflecting a deliberate push to broaden and deepen its pipeline, but also increasing scientific and execution risk if data do not meet expectations.

Summary

Lexeo is an early, high‑risk, research‑driven biotech with no current revenue and a financial profile shaped by sizeable operating losses and negative cash flow. The balance sheet has improved post‑IPO and provides a runway, but the business will likely need additional capital over time unless its programs progress successfully and open partnership or other funding options. Strategically, the company is tightly focused on genetically defined cardiovascular and neurodegenerative diseases, supported by a differentiated gene therapy platform, academic partnerships, and favorable regulatory designations. The long‑term outcome will depend heavily on upcoming clinical readouts, the ability to move into pivotal trials, and the company’s skill in scaling manufacturing and managing cash through a lengthy, uncertain development path.

NEWS

November 5, 2025 · 7:36 AM UTC

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

Read more

October 20, 2025 · 4:05 PM UTC

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering

Read more

October 16, 2025 · 11:29 PM UTC

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

Read more

October 16, 2025 · 4:32 PM UTC

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Read more

October 7, 2025 · 6:00 AM UTC

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Read more